Medicare's actuaries expect the drug Leqembi to cost the traditional Medicare program around $550 million in 2024 and the entire Medicare program $3.5 billion in 2025.
Three advocacy groups are pushing the Biden administration to use federal laws to license patents on a cancer treatment to outside manufacturers in order to produce lower-cost versions.
The reports of an Ozempic baby boom are anecdotal, and it's not known how widespread the phenomenon is. Experts say significant weight loss can affect fertility.
The FDA on Thursday approved the novel antibiotic Zevtera (ceftobiprole medocaril sodium for injection) for treating serious bacterial infections in adults and children.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.